ArticleHormones (Athens, Greece)2026
Pseudohypoaldosterism: demystification using network medicine and proposed diagnostic panels.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePseudohypoaldosteronism (PHA) is a rare hereditary channelopathy characterized by renal tubular dysfunction that impairs sodium reabsorption and promotes excessive potassium retention. This imbalance often results in life-threatening electrolyte disturbances during infancy, although symptoms tend to improve with age. The disease has distinct genetic forms, most commonly linked to pathogenic variants in genes encoding epithelial sodium channel (ENaC) subunits, the mineralocorticoid receptor gene NR3C2, and the CUL3, WNK1, WNK4, or KLHL3 genes. More recently, cases involving digenic co-expression defects have been reported, suggesting a broader molecular pathogenic basis. The objective of this study was to investigate the underlying mechanisms of PHA and to assess whether additional genetic contributors may participate in disease pathogenesis.
methodsA systems medicine approach was applied, combining interaction network construction with enrichment analyses.
resultsA high confidence interactome consisting of 53 nodes was generated, with CALM3 and SCN2A identified as central hubs. Enrichment analysis highlighted biological processes and pathways related to membrane depolarization, sodium ion transport, aldosterone-regulated sodium reabsorption, and gene expression in renal tissue. Two diagnostic panels were designed, namely, PHA-X (NGS-based incorporating CNV detection and ACMG/AMP curation) and PHA-4T (disease-specific databases).
conclusionFindings support the conception of PHA as a network-level disorder rather than resulting from isolated mutations, offering new perspectives for diagnosis and therapy development.
Indexed as
Identifiers
41569463What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.